North Crest Asset Manangement, LLC Halozyme Therapeutics, Inc. Transaction History
North Crest Asset Manangement, LLC
- $3.19 Billion
- Q4 2024
A detailed history of North Crest Asset Manangement, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, North Crest Asset Manangement, LLC holds 29,852 shares of HALO stock, worth $1.68 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
29,852
Previous 29,852
-0.0%
Holding current value
$1.68 Million
Previous $1.71 Million
16.4%
% of portfolio
0.04%
Previous 0.05%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
539Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$994 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$728 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$374 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$229 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$192 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.86B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...